litlas
ログインアカウント作成

Ofer Shpilberg

1995–2025 年に発表

72
論文数
18,650
被引用数
60
h 指数
69
i10 指数

被引用数

Ofer Shpilberg の年別被引用数1948 年: 被引用 1 件1996 年: 被引用 2 件1997 年: 被引用 3 件1998 年: 被引用 10 件1999 年: 被引用 17 件2000 年: 被引用 23 件2001 年: 被引用 18 件2002 年: 被引用 28 件2003 年: 被引用 37 件2004 年: 被引用 17 件2005 年: 被引用 23 件2006 年: 被引用 13 件2007 年: 被引用 37 件2008 年: 被引用 52 件2009 年: 被引用 88 件2010 年: 被引用 118 件2011 年: 被引用 132 件2012 年: 被引用 117 件2013 年: 被引用 166 件2014 年: 被引用 188 件2015 年: 被引用 167 件2016 年: 被引用 163 件2017 年: 被引用 143 件2018 年: 被引用 128 件2019 年: 被引用 531 件2020 年: 被引用 467 件2021 年: 被引用 439 件2022 年: 被引用 364 件2023 年: 被引用 214 件2024 年: 被引用 391 件2025 年: 被引用 162 件2026 年: 被引用 1 件1949〜1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,634 件、この内訳の 22.2%ドイツ: 引用元論文 524 件、この内訳の 7.1%イタリア: 引用元論文 488 件、この内訳の 6.6%中国: 引用元論文 443 件、この内訳の 6%イギリス: 引用元論文 443 件、この内訳の 6%フランス: 引用元論文 412 件、この内訳の 5.6%スペイン: 引用元論文 314 件、この内訳の 4.3%カナダ: 引用元論文 260 件、この内訳の 3.5%オランダ: 引用元論文 232 件、この内訳の 3.2%スイス: 引用元論文 215 件、この内訳の 2.9%オーストラリア: 引用元論文 211 件、この内訳の 2.9%日本: 引用元論文 157 件、この内訳の 2.1%
0%22.2%その他 27.6%

機関

分野

  • Medicine83.1%
  • Biochemistry, Genetics and Molecular Biology10.2%
  • Immunology and Microbiology3.7%
  • Materials Science0.9%
  • Engineering0.5%
  • Economics, Econometrics and Finance0.4%
  • その他1.2%

トピック

  • Lymphoma Diagnosis and Treatment11.4%
  • CAR-T cell therapy research6.5%
  • Multiple Myeloma Research and Treatments6.4%
  • Chronic Lymphocytic Leukemia Research3.8%
  • Protein Degradation and Inhibitors3.6%
  • CNS Lymphoma Diagnosis and Treatment3.1%
  • その他65.2%

共著者

全論文

検索で開く
  1. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

    著者: Christian Gisselbrecht, Bertram Glaß, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, André Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg, Dávid Ma, Josette Brière, Craig H. Moskowitz, Norbert Schmitz - Journal of Clinical Oncology 2010 被引用: 1,622

  2. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

    著者: Yaël C. Cohen, Mor Zada, Shuang-Yin Wang, Chamutal Bornstein, Eyal David, Adi Moshe, Baoguo Li, Shir Shlomi-Loubaton, Moshe E. Gatt, Chamutal Gur, Noa Lavi, Chezi Ganzel, Efrat Luttwak, Evgeni Chubar, Ory Rouvio, Iuliana Vaxman, Oren Pasvolsky, Mouna Ballan, Tamar Tadmor, Anatoly Nemets, Osnat Jarchowcky-Dolberg, Olga Shvetz, Meirav Laiba, Ofer Shpilberg, Najib Dally, Irit Avivi, Assaf Weiner, Ido Amit - Nature Medicine 2021 被引用: 246

  3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    著者: Michael Pfreundschuh, Lorenz Trümper, Anders Österborg, Ruth Pettengell, Marek Trněný, Kevin Imrie, Dávid Ma, Devinder Gill, Jan Walewski, Pier Luigi Zinzani, Rolf A. Stahel, Stein Kvaløy, Ofer Shpilberg, Ulrich Jaeger, Mads Hansen, Tuula Lehtinen, Armando López‐Guillermo, Claudia Corrado, Adriana Scheliga, Nöel Milpied, Myriam Mendila, Michelle Rashford, Evelyn Kuhnt, Markus Loeffler - The Lancet Oncology 2006 被引用: 2,085

  4. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

    著者: Gaurav Goyal, Mark Heaney, Matthew Collin, Fleur Cohen‐Aubart, Augusto Vaglio, Benjamin H. Durham, Oshrat Hershkovitz‐Rokah, Michael Girschikofsky, Eric D. Jacobsen, Kazuhiro Toyama, Aaron M. Goodman, Paul C. Hendrie, Xinxin Cao, Juvianee Estrada‐Veras, Ofer Shpilberg, André Abdo, Mineo Kurokawa, Lorenzo Dagna, Kenneth L. McClain, Roei David Mazor, Jennifer Picarsic, Filip Jankú, Ronald S. Go, Julien Haroche, Eli L. Diamond - Blood 2020 被引用: 401

  5. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

    著者: Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, Anders Österborg, Marek Trněný, Lois E. Shepherd, Devinder Gill, Jan Walewski, Ruth Pettengell, Ulrich Jaeger, Pier Luigi Zinzani, Ofer Shpilberg, Stein Kvaløy, Peter de Nully Brown, Rolf A. Stahel, Nöel Milpied, Armando López‐Guillermo, Viola Poeschel, Sandra Graß, Markus Loeffler, Niels Murawski - The Lancet Oncology 2011 被引用: 811

  6. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: M. Dreyling, Elı́as Campo, Olivier Hermine, Mats Jerkeman, Steven Le Gouill, Simon Rule, Ofer Shpilberg, Jan Walewski, Marco Ladetto - Annals of Oncology 2017 被引用: 736

  7. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

    著者: Martin Dreyling, Jeanette K. Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trněný, Vibeke Vergote, Ofer Shpilberg, María Gomes da Silva, Sirpa Leppä, Linmiao Jiang, Stephan Stilgenbauer, Andrea Kerkhoff, Ron D. Jachimowicz, Melania Celli, Georg Heß, Luca Arcaini, Carlo Visco, Tom van Meerten, Stefan Wirths, Pier Luigi Zinzani, Urban Novak, Peter Herhaus, Fabio Benedetti, Kristina Sonnevi, Christine Hanoun, Matthias Hänel, Judith Dierlamm, Christiane Pott, Wolfgang Hiddemann, Döndü Gözel, Christian Schmidt, Michael Unterhalt, Marco Ladetto, Eva Hoster - The Lancet 2024 被引用: 136

  8. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

    著者: Éric Van Den Neste, Norbert Schmitz, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, Nöel Milpied, John Radford, Nicolas Ketterer, Ofer Shpilberg, Ulrich Dührsen, Dávid Ma, Josette Brière, Catherine Thiéblemont, Gilles Salles, Craig H. Moskowitz, B. Glaß, Christian Gisselbrecht - Bone Marrow Transplantation 2015 被引用: 316

  9. Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

    著者: B Coiffier, E.A. Osmanov, Xin Hong, Adriana Scheliga, Jiřı́ Mayer, F. Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Shoko Vos, Michael Crump, Ofer Shpilberg, DL Esseltine, E. Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Y. A. Elsayed, Pier Luigi Zinzani, Lym study investigators, Marina. Liberati Anna - The Lancet Oncology 2011 被引用: 1,626

  10. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

    著者: Viola Poeschel, Gerhard Held, Marita Ziepert, Mathias Witzens‐Harig, Harald Holte, Lorenz Thurner, Peter Borchmann, Andreas Viardot, Martin Soekler, Ulrich Keller, Christian Schmidt, Lorenz Truemper, Rolf Mahlberg, Reinhard Marks, Heinz‐Gert Hoeffkes, Bernd Metzner, Judith Dierlamm, Norbert Frickhofen, Mathias Haenel, Andreas Neubauer, Michael Kneba, Francesco Merli, Alessandra Tucci, Peter de Nully Brown, Massimo Federico, Eva Lengfelder, Alice Di Rocco, Ralf Ulrich Trappe, Andreas Rosenwald, Christian Berdel, Martin Maisenhoelder, Ofer Shpilberg, Josif Amam, Konstantinos Christofyllakis, Frank Hartmann, Niels Murawski, Stephan Stilgenbauer, Maike Nickelsen, Gerald Wulf, Bertram Glaß, Norbert Schmitz, Bettina Altmann, Markus Loeffler, Michael Pfreundschuh - The Lancet 2019 被引用: 253

  11. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells

    著者: Kalimuthu Kalishwaralal, Bat-Chen R. Avraham-Lubin, Andrii Bazylevich, Gary Gellerman, Ofer Shpilberg, Galia Luboshits, Michael A. Firer - Journal of Nanobiotechnology 2018 被引用: 180

  12. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    著者: Meletios Α. Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Katja Weisel, Jesús F. San Miguel, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, María‐Victoria Mateos, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Morio Matsumoto, Ka Lung Wu, Kenneth C. Anderson, Ying‐Ming Jou, Alex Ganetsky, Anil Singhal, Paul G. Richardson - Blood Cancer Journal 2020 被引用: 153

  13. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

    著者: Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva, Meletios Α. Dimopoulos, Ofer Shpilberg, Martin Kropff, Ivan Špıčka, Maria Teresa Petrucci, Antonio Palumbo, Olga Samoilova, Anna Dmoszyńska, Abdulkadyrov Km, Rik Schots, Bin Jiang, María-Victoria Mateos, Kenneth C. Anderson, Dixie Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, Paul G. Richardson - New England Journal of Medicine 2008 被引用: 1,904

  14. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

    著者: Martin Dreyling, Jeanette K. Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trněný, Vibeke Vergote, Melania Celli, Ofer Shpilberg, María Gomes da Silva, Sirpa Leppä, Linmiao Jiang, Christiane Pott, Wolfgang Hiddemann, Döndü Gözel, Christian Schmidt, Michael Unterhalt, Marco Ladetto, Eva Hoster - Blood 2022 被引用: 84

  15. A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

    著者: Francine M. Foss, Ranjana H. Advani, Madeleine Duvic, Kenneth B. Hymes, Tanin Intragumtornchai, Arnuparp Lekhakula, Ofer Shpilberg, Adam Lerner, Robert J. Belt, Eric D. Jacobsen, Guy Laurent, Dina Ben‐Yehuda, M. Beylot‐Barry, Uwe Hillen, Poul Knoblauch, Gajanan Bhat, Shanta Chawla, Lee F. Allen, Brad Pohlman - British Journal of Haematology 2014 被引用: 190

  16. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    著者: Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michèle Cavo, Meral Beksaç, Wojciech Legieć, Anna Marina Liberati, Hartmut Goldschmidt, Andrew R. Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria Teresa Petrucci, Donna Reece, Darrell White, María‐Victoria Mateos, Ivan Špıčka, Mihaela Lazaroiu, Jesús G. Berdeja, Jonathan L. Kaufman, Ying‐Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michèle Cavo, Meral Beksaç, Wojciech Legieć, Anna Marina Liberati, Hartmut Goldschmidt, Andrew R. Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria Teresa Petrucci, Donna Reece, Darrell White, María‐Victoria Mateos, Ivan Špıčka, Mihaela Lazaroiu, Jesús G. Berdeja, Jonathan L. Kaufman, Ying‐Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Irwindeep Sandhu, Monika Podhorecka, Antonio Palumbo, Adi Shacham‐Abulafia, Iuliana Vaxman, Ofer Shpilberg, Britta Besemer, Maurizio Martelli, Roberto Foà, Paolo de Fabritiis, Tommaso Caravita di Toritto, Emanuil Gheorghita, Albert Oriol, Philip Rowlings, Angelucci Emanuele, Angelo Michele Carella, Massimo Offidani, Joan Bladé, Luis Felipe Casado, Heather Oakervee, Victoria Panelli, Luís Meza, Thomas Kühr, Miguel Granell, Don Benson, Rajesh Nair, Viran Holden, J. N. Reeves, Richard Eek, Patricia Walker, John Catalano, András Rosta, Ewa Lech‐Marańda, Christy Samaras, Tony Reiman, Robert Weaver, Péter Ács, Andrew Grigg, Bernard De Prijck, Martha Louzada, Leonard Minuk, Michaël Sébag, Martine Klausmann, Manfred Welslau, Andrzej Hellmann, Catalin Danaı̈la, Pamela S. Becker, William Bensinger ほか 178 名 - The Lancet Haematology 2022 被引用: 47

  17. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

    著者: Robert H. Collins, Ofer Shpilberg, William R. Drobyski, David Porter, Sergio Giralt, Richard E. Champlin, Stacey Goodman, S N Wolff, Hu Wh, Catherine M. Verfaillie, Alan F. List, William S. Dalton, Nadine Ognoskie, Angela Chetrit, Joseph H. Antin, John Nemunaitis - Journal of Clinical Oncology 1997 被引用: 1,258

  18. MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis

    著者: Ran Weissman, Eli L. Diamond, Julien Haroche, Benjamin H. Durham, Fleur Cohen, Justin J. Buthorn, Zahir Amoura, Jean‐François Emile, Roei David Mazor, Noam Shomron, Omar Abdel‐Wahab, Ofer Shpilberg, Oshrat Hershkovitz‐Rokah - Leukemia 2021 被引用: 25

  19. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    著者: Valeria Santini, António Almeida, Aristoteles Giagounidis, Stefanie Gröpper, Anna Jonášová, Norbert Vey, Ghulam J. Mufti, Rena Buckstein, Moshe Mittelman, Uwe Platzbecker, Ofer Shpilberg, Ron Ram, Consuelo del Cañizo, Norbert Gattermann, Keiya Ozawa, Alberto Risueño, Kyle J. MacBeth, Jianhua Zhong, Francis Séguy, Albert Hoenekopp, C.L. Beach, Pierre Fenaux - Journal of Clinical Oncology 2016 被引用: 213

  20. High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

    著者: Susan O’Brien, Gary J. Schiller, John Lister, Lloyd E. Damon, Stuart L. Goldberg, Walter E. Aulitzky, Dina Ben‐Yehuda, Wendy Stock, Steven Coutré, Dan Douer, Leonard T. Heffner, Melissa L. Larson, Karen Seiter, Scott E. Smith, Sarit Assouline, Philip Kuriakose, Lori J. Maness, Arnon Nagler, Jacob M. Rowe, Markus Schaich, Ofer Shpilberg, Karen Yee, Guenter Schmieder, Jeffrey A. Silverman, Deborah Thomas, Steven R. Deitcher, Hagop M. Kantarjian - Journal of Clinical Oncology 2012 被引用: 188

  21. Role and prognostic significance of the Ki‐67 index in non‐Hodgkin's lymphoma

    著者: Adi Broyde, Olga Boycov, Yulia Strenov, Elimelech Okon, Ofer Shpilberg, Osnat Bairey - American Journal of Hematology 2009 被引用: 150

  22. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

    著者: Jesús F. San Miguel, Joan Bladé, Ofer Shpilberg, Sebastian Grosicki, Frédéric Maloisel, Chang‐Ki Min, Marta Polo Zarzuela, Tadeusz Robak, Sripada V.S.S Prasad, Yeow Tee Goh, Jacob P. Laubach, Andrew Spencer, María‐Victoria Mateos, Antonio Palumbo, T. A. Puchalski, Manjula Reddy, Clarissa Uhlar, Xiang Qin, Helgi van de Velde, Hong Xie, Robert Z. Orlowski - Blood 2014 被引用: 141

  23. Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

    著者: Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, André Bosly, Nöel Milpied, John Radford, Nicolas Ketterer, Ofer Shpilberg, Ulrich Dührsen, Hans Hagberg, Daniel David, Andreas Viardot, Ray M. Lowenthal, Josette Brière, Gilles Salles, Craig H. Moskowitz, Bertram Glaß - Journal of Clinical Oncology 2012 被引用: 273

  24. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis

    著者: Pia Raanani, Anat Gafter‐Gvili, Mical Paul, Isaac Ben‐Bassat, Leonard Leibovici, Ofer Shpilberg - Leukemia & lymphoma/Leukemia and lymphoma 2009 被引用: 149